Isoniazid in Pulmonary Tuberculosis.
—The second report of the Medical Research Council's Tuberculosis Chemotherapy Trials Committee on isoniazid in the treatment of pulmonary tuberculosis (Brit. M. J. 1:521, 1953) is based on the findings in 364 patients after three months' treatment. Three forms of treatment were used: 142 patients were treated with streptomycin (1 gm. daily) and isoniazid (100 mg. twice daily); 102 with streptomycin (1 gm. daily) and p-aminosalicylic acid (5 gm. four times daily); and 120 with isoniazid (100 mg. twice daily) alone. The criteria for acceptance of a patient for inclusion in the trial were as follows: 1. Tubercle bacilli had to be demonstrated. 2. The tubercle bacilli could not be streptomycin-resistant or p-aminosalicylic acid-resistant. 3. The patient could not have had more than 15 gm. of streptomycin and/or 300 gm. of p-aminosalicylic acid within the previous three months, and not more than